Phase II trial of iboctadekin (rhIL-18) on a daily X 5 schedule in metastatic melanoma (MM).

J. M. Kirkwood, R. Kefford, T. Logan, P. N. Mainwaring, M. Millward, A. C. Pavlick, M. M. Dar, S. Kathman, K. Laubscher, W. Bell

Research output: Contribution to journalMeeting abstract

Original languageEnglish
Pages (from-to)10043-10043
Number of pages1
JournalJournal of Clinical Oncology
Issue number18 supplement
Publication statusPublished - 20 Jun 2006
Externally publishedYes
Event42nd Annual Meeting of the American-Society-of-Clinical-Oncology - Atlanta, Gabon
Duration: 2 Jun 20066 Jun 2006

Cite this